Boston Scientific (NYSE: BSX) CEO gets major share awards and tax withholdings
Rhea-AI Filing Summary
Boston Scientific Corp Chairman, President & CEO Michael F. Mahoney reported multiple equity award and vesting transactions. On February 13, 2026, he acquired 132,190 shares of common stock as a grant and another 8,832 shares through the conversion of restricted stock units, while 132,099 shares of common stock were withheld at $74.73 per share to cover tax obligations.
On February 14, 2026, 16,524 restricted stock units converted into 16,524 common shares, with 7,990 shares withheld for taxes at $74.73 per share. On February 16, 2026, 16,265 restricted stock units converted into common stock and 7,865 shares were similarly withheld for taxes at $74.73 per share.
The filing notes performance share units granted in February 2023 under organic net sales and total shareholder return programs, for which performance and service conditions were satisfied as of February 13, 2026. An additional 213,679 common shares are reported as held indirectly by trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 16,265 | $0.00 | -- |
| Exercise | Common Stock | 16,265 | $0.00 | -- |
| Tax Withholding | Common Stock | 7,865 | $74.73 | $588K |
| Exercise | Restricted Stock Units | 16,524 | $0.00 | -- |
| Exercise | Common Stock | 16,524 | $0.00 | -- |
| Tax Withholding | Common Stock | 7,990 | $74.73 | $597K |
| Exercise | Restricted Stock Units | 8,832 | $0.00 | -- |
| Grant/Award | Common Stock | 132,190 | $0.00 | -- |
| Grant/Award | Common Stock | 132,190 | $0.00 | -- |
| Exercise | Common Stock | 8,832 | $0.00 | -- |
| Tax Withholding | Common Stock | 132,099 | $74.73 | $9.87M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
